PREVENTION OF CARDIAC DISEASE BY SUBCUTANEOUS DEFEROXAMINE IN PATIENTS WITH THALASSEMIA MAJOR

被引：255
|
作者：
WOLFE, L
OLIVIERI, N
SALLAN, D
COLAN, S
ROSE, V
PROPPER, R
FREEDMAN, MH
NATHAN, DG
机构：
[1] CHILDRENS HOSP MED CTR, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA
[2] DANA FARBER CANC INST, BOSTON, MA USA
[3] HOSP SICK CHILDREN, DIV HEMATOL, TORONTO M5G 1X8, ONTARIO, CANADA
[4] HOSP SICK CHILDREN, DEPT CARDIOL, TORONTO M5G 1X8, ONTARIO, CANADA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 1985年 / 312卷 / 25期
关键词：
D O I：
10.1056/NEJM198506203122503
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1600 / 1603
页数：4
相关论文
共 50 条
  • [21] Comparison of cardiac dysfunction in thalassemia major patients using deferoxamine or deferiprone as an iron-chelating agent
    Josep, Rosalina
    Wahidiyat, Pustika Amalia
    Trihono, Partini Pudjiastuti
    Yanuarso, Piprim B.
    PAEDIATRICA INDONESIANA, 2012, 52 (05) : 272 - 279
  • [22] REGRESSION OF CARDIAC-INSUFFICIENCY AFTER AMBULATORY INTRAVENOUS DEFEROXAMINE IN THALASSEMIA MAJOR
    WACKER, P
    HALPERIN, DS
    BALMERRUEDIN, D
    OBERHANSLI, I
    WYSS, M
    CHEST, 1993, 103 (04) : 1276 - 1278
  • [23] CONTINUOUS SUBCUTANEOUS DEFEROXAMINE TREATMENT IN THALASSEMIA MAJOR - DECREASE IN HEMOSIDEROSIS AND IMPROVEMENT IN LIVER-FUNCTION
    KRUGER, N
    ULLRICH, D
    TILLMANN, W
    SCHROTER, W
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1985, 110 (48) : 1848 - 1851
  • [24] PROLONGED SURVIVAL IN PATIENTS WITH BETA-THALASSEMIA MAJOR TREATED WITH DEFEROXAMINE
    EHLERS, KH
    GIARDINA, PJ
    LESSER, ML
    ENGLE, MA
    HILGARTNER, MW
    JOURNAL OF PEDIATRICS, 1991, 118 (04): : 540 - 545
  • [25] Deferiprone versus deferoxamine in patients with thalassemia major: A randomized clinical trial
    Maggio, A
    D'Amico, G
    Morabito, A
    Capra, M
    Ciaccio, C
    Cianciulli, P
    Di Gregorio, F
    Garozzo, G
    Malizia, R
    Magnano, C
    Mangiagli, A
    Quarta, G
    Rizzo, M
    D'Ascola, DG
    Rizzo, A
    Midiri, M
    BLOOD CELLS MOLECULES AND DISEASES, 2002, 28 (02) : 196 - 208
  • [26] Compliance with Deferoxamine Therapy and Thyroid Dysfunction of Patients with β-Thalassemia Major in Syria
    Yassouf, M. Yousuf
    Alquobaili, Faizeh
    Kabalan, Younes
    Mukhalalaty, Yasser
    HEMOGLOBIN, 2019, 43 (03) : 218 - 221
  • [27] Sensory neural hearing loss in β-thalassemia major patients treated with deferoxamine
    Shamsian, Bibi Shahin
    Aminasnafi, Ali
    Moghadassian, Habiballah
    Gachkar, Latif
    Arzanian, M. Taghi
    Alavi, Samin
    Esfehani, Hossein
    Garallahi, Farnoush
    Amini, Reyhaneh
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2008, 25 (06) : 502 - 508
  • [28] PULMONARY SYNDROME IN PATIENTS WITH THALASSEMIA MAJOR RECEIVING INTRAVENOUS DEFEROXAMINE INFUSIONS
    FREEDMAN, MH
    GRISARU, D
    OLIVIERI, N
    MACLUSKY, I
    THORNER, PS
    AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1990, 144 (05): : 565 - 569
  • [29] EFFICACY OF DEFEROXAMINE IN PREVENTING COMPLICATIONS OF IRON OVERLOAD IN PATIENTS WITH THALASSEMIA MAJOR
    BRITTENHAM, GM
    GRIFFITH, PM
    NIENHUIS, AW
    MCLAREN, CE
    YOUNG, NS
    TUCKER, EE
    ALLEN, CJ
    FARRELL, DE
    HARRIS, JW
    NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (09): : 567 - 573
  • [30] Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial
    Tsakok, AD
    BLOOD CELLS MOLECULES AND DISEASES, 2004, 32 (01) : 139 - 140
12345